Sanovas, Inc.

Sanovas is developing the next generation of minimally invasive surgical tools and technologies. Our revolutionary, patented products enable surgeons to visualize, diagnose, measure and treat obstructed passageways in areas of the body that are inaccessible using currently marketed surgical tools. These products are designed to provide surgeons with faster, less invasive, lower risk and more cost effective interventional treatments. The company is initially targeting the pulmonary market, which includes treatment of lung cancer, COPD, asthma and cystic fibrosis. Future addressable markets include treatment of diseases and disorders of the six major organ systems of the tubular anatomy. At the heart of Sanovas' scientific advancements is the miniaturization of tools for minimally invasive surgery. Sanovas' products extend access beyond current limits enabling surgeons to perform therapeutic intervention in small, one-millimeter diameter regions of the anatomy that were previously inaccessible and heretofore not possible to access.

• Employees 14
• Founded 2009
• Annual Revenue $5000000
• Total Funding $39802221